Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : John Dessauer's Investors World -- Ignore unavailable to you. Want to Upgrade?

To: Keith Garlitz who wrote (1521)	8/26/1998 12:05:00 PM
From: Paul Lee	Respond to of 2346

Pharmaceutical Marketing Reports Results for Fiscal 1998; Successful Completion of Sale of Non-US Assets to IMS Health NEW YORK, Aug. 26 /PRNewswire/ -- Pharmaceutical Marketing Services Inc. (PMSI) (Nasdaq: PMRX - news), a leading international provider of information services to the pharmaceutical and healthcare industry, today reported its financial results for its fourth quarter of fiscal 1998 and for the year ended June 30, 1998. The net loss for the three months ended June 30, 1998 was $0.4 million, or $0.03 per share compared with net income of $1.9 million or $0.14 per share for the fourth quarter of 1997, reflecting continuing investment to support the development of Source Europe and divestitures of business during the year. The net loss for the year was $0.3 million or $0.02 per share compared with a net loss of $5.3 million or $0.40 per share for fiscal 1997. Revenues of $18.8 million for the three months ended June 30, 1998, were 20 percent above revenues in the same period of the previous year after excluding those businesses divested during the year. Scott-Levin, the Company's US subsidiary, a leading provider of market research and managed care information services to the US pharmaceutical industry, generated revenue growth of 21 percent over the previous year. Revenues for the year ended June 30, 1998 were $78.0 million, a decline of $20.5 million (21 percent) compared with revenues for the year ended June, 30 1997. The decrease resulted from those businesses divested during the year. In the year ended June 30, 1997 revenues from the divested businesses totaled $37.3 million. The divestments masked revenue growth in the Company's ongoing businesses, in particular Scott-Levin in the US and the Company's targeting business in Japan, both of which experienced revenue growth of more than 20 percent compared with the prior year. Currency exchange rate movements negatively impacted the year's revenue by $2.3 million, or 3 percent. ''This brings to an end a complicated year in which much has been accomplished to build intrinsic shareholder value,'' commented Dennis Turner, PMSI's Chief Executive Officer. ''However, the financial performance of our ongoing business compared with last year is being obscured by the significant re-organization and divestment activity. During the year we have divested our international publishing business, our French point of sale business and our interest in the Source joint venture and OTC business in the US, recognizing a pre-tax gain of $34 million. We also acquired Source Europe, a business developing prescription databases in certain major European markets. In addition, since year end, we have divested all of our businesses outside the United States in the transaction with IMS Health.'' On August 5, 1998, the Company announced completion of the sale of its non-US assets (including Source Europe) to IMS Health (NYSE: RX - news) for consideration of $75 million comprising approximately 1.2 million shares of IMS Health common stock. PMSI remains a publicly traded corporation comprising Scott-Levin, a leading provider of market research and managed care services to the pharmaceutical industry in the US. The Scott-Levin business delivered pre-tax operating profits of $6.6 million on revenues of $26.2 million in the year to June 30,1998, a growth of 34 percent and 21 percent respectively compared with fiscal 1997. ''Given the major issues we faced in completing the sale of the entire business to Cognizant, announced on March 23, 1998, and the uncertain timetable for their resolution, we believe the transaction we have now completed with IMS Health offers the best way forward for PMSI,'' said Mr. Turner. ''With the substantial proceeds from this transaction, together with PMSI's strong existing asset base, and our rapidly growing Scott-Levin business in the United States, we believe we have created an excellent vehicle to build value for PMSI's shareholders.'' At June 30, 1998, the Company had $112 million in cash and marketable securities, an increase of $47 million over June 30, 1997. This excludes the consideration received from the transaction with IMS Health. PMSI provides a range of information and market research services to pharmaceutical and healthcare companies in the United States to enable them to optimize their sales and marketing performance. Most of the Company's information services are generated from proprietary databases which contain unique prescription, physician, managed care and healthcare market data.